CTMX CytomX Therapeutics Inc

Price (delayed)

$3.185

Market cap

$693.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.41

Enterprise value

$665.88M

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 25

CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. CytomX is developing a novel class of investigational conditionally activated antibody therapeutics, ...

Highlights
CTMX's debt has dropped by 65% year-on-year and by 33% since the previous quarter
The EPS has plunged by 184% YoY and by 173% from the previous quarter
CTMX's revenue has dropped by 76% year-on-year and by 53% since the previous quarter

Key stats

What are the main financial stats of CTMX

CTMX stock price

How has the CytomX Therapeutics stock price performed over time
Intraday
-1.09%
1 week
-14.15%
1 month
-23.8%
1 year
26.89%
YTD
-25.23%
QTD
-32.23%

Financial performance

How have CytomX Therapeutics's revenue and profit performed over time
Revenue
$35.54M
Gross profit
$35.54M
Operating income
-$64.66M
Net income
-$59.14M
Gross margin
100%
Net margin
-166.4%
The operating income has dropped by 189% since the previous quarter
CTMX's revenue has dropped by 76% year-on-year and by 53% since the previous quarter
The gross profit has dropped by 76% year-on-year and by 53% since the previous quarter

Price vs fundamentals

How does CTMX's price correlate with its fundamentals

Growth

What is CytomX Therapeutics's growth rate over time

Valuation

What is CytomX Therapeutics stock price valuation
P/E
N/A
P/B
1.69
P/S
15.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.74
The EPS has plunged by 184% YoY and by 173% from the previous quarter
The stock's price to book (P/B) is 58% less than its last 4 quarters average of 4.1
CTMX's revenue has dropped by 76% year-on-year and by 53% since the previous quarter
The stock's P/S is 69% more than its last 4 quarters average of 9.5

Efficiency

How efficient is CytomX Therapeutics business performance
CTMX's return on assets has dropped by 191% year-on-year and by 110% since the previous quarter
The ROIC has shrunk by 68% QoQ
CTMX's ROE has dropped by 66% since the previous quarter

Dividends

What is CTMX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTMX.

Financial health

How did CytomX Therapeutics financials performed over time
CTMX's total assets has soared by 137% from the previous quarter
The company's total liabilities fell by 46% YoY and by 25% QoQ
CTMX's debt is 99% smaller than its equity
The debt to equity has dropped by 97% year-on-year and by 75% since the previous quarter
CTMX's debt has dropped by 65% year-on-year and by 33% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.